# Maxinovel Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/maxinovel-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Guangzhou, China
- Website: www.maxinovel.com
- Total disclosed funding: $14M
- Latest round: Series C (Oct 19, 2022)
- Investors on record: 9

## About

Established in 2016 and based in Guangzhou, China, Maxinovel Pharmaceuticals is a medical company that focuses on the research and development of small molecule targeted drugs and tumor immune drugs. The management and technical teams have over 20 years of experience in drug discovery and clinical management. The company has established R&D and operation centers in Shanghai, Guangzhou and Shenzhen. And, we also have offices in the United States and Australia. In April 2018, this company received orphan drug status from the U.S. Food and Drug Administration (FDA) for its clinical product Max-40279. The company's co-founder, Chairman and President, Yuguang Wang, graduated from the University of Kansas with over 30 years of experience in new drug development and management, and was the recipient of the 2008 Edison Patent Award for invention.

The company's main business is the research and development of acute myeloid leukemia, colorectal cancer, gastric cancer, lung cancer and other fields, products involving tumor targeting, tumor immunity, skin drugs and other innovative drugs. Their self-developed products such as acute myeloid leukemia drug MAX-4, solid tumor targeted therapy drug MAX-5, baldness hair drug MAX-3 and radioligand therapy drug MAX-8.

The company generates revenue from producing small molecule innovative drugs: oral drug, transdermal drug and radiopharmaceuticals & radio diagnostics.

## Funding rounds

- Series C, Oct 19, 2022, $14M — DYEE Capital, Lapam Capital, Zhongxin Capital, Tibet Zhifan
- Series C, Jan 4, 2021 — BVCF Capital, DYEE Capital, Lapam Capital, Youchoose Capital
- Series B, Jul 11, 2019 — Zhongguancun Venture Capital, Lapam Capital
- Series A, Feb 9, 2018 — Share Capital, Ruimeng Venture Capital

## Investors

- Share Capital (https://capitalatlas.ai/funds/share-capital) — Series A
- Ruimeng Venture Capital (https://capitalatlas.ai/funds/ruimeng-venture-capital) — Series A
- Zhongguancun Venture Capital (https://capitalatlas.ai/funds/zhongguancun-venture-capital) — Series B
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series B, Series C
- BVCF Capital — Series C
- DYEE Capital (https://capitalatlas.ai/funds/dyee-capital) — Series C
- Youchoose Capital — Series C
- Zhongxin Capital — Series C
- Tibet Zhifan — Series C